Copyright
©The Author(s) 2023.
World J Hepatol. Aug 27, 2023; 15(8): 964-972
Published online Aug 27, 2023. doi: 10.4254/wjh.v15.i8.964
Published online Aug 27, 2023. doi: 10.4254/wjh.v15.i8.964
Characteristic | TAF, n = 214 | ETV, n = 122 | P value |
Age in yr | 43.38 ± 10.42 | 49.96 ± 11.82 | 0.001 |
Male | 158 (73.83) | 96 (78.69) | 0.387 |
BMI in kg/m2 | 22.97 ± 2.93 | 23.78 ± 3.30 | 0.152 |
Smoking | 16 (7.48) | 15 (12.30) | 0.203 |
Drinking | 13 (6.07) | 14 (11.48) | 0.123 |
ALT in U/L | 36.60 ± 36.87 | 30.44 ± 20.00 | 0.089 |
AST in U/L | 28.01 ± 26.41 | 24.50 ± 13.58 | 0.172 |
logHBsAg in ng/mL | 3.07 ± 0.92 | 3.04 ± 0.84 | 0.787 |
logDNA in IU/mL | 1.94 ± 1.23 | 1.86 ± 1.05 | 0.56 |
CREA in μmol/L | 73.68 ± 15.87 | 74.82 ± 16.78 | 0.535 |
UA in μmol/L | 353.52 ± 89.10 | 357.23 ± 84.29 | 0.708 |
GFR in mL/min | 103.48 ± 15.01 | 97.86 ± 14.17 | 0.001 |
CK in U/L | 157.23 ± 444.75 | 122.91 ± 71.31 | 0.401 |
FBG in mmol/L | 5.18 ± 0.80 | 5.52 ± 1.61 | 0.011 |
Concurrent diseases | |||
Hypertension | 17 (7.94) | 21 (17.21) | 0.016 |
DM | 20 (9.35) | 13 (10.66) | 0.844 |
NAFLD | 75 (35.05) | 32 (26.23) | 0.122 |
Cirrhosis | 54 (25.23) | 50 (40.98) | 0.004 |
Characteristic | TAF, n = 214, statistic | P value1 | ETV, n = 122, statistic | P value1 | P value2 |
Pre-Tx TCHO in mmol/L | 4.51 ± 0.93 | 0.001 | 4.41 ± 1.03 | 0.275 | 0.376 |
Post-Tx TCHO in mmol/L | 4.67 ± 0.90 | 4.36 ± 1.05 | 0.006 | ||
Pre-Tx TG in mmol/L | 1.25 ± 0.67 | 0.014 | 1.33 ± 0.75 | 0.052 | 0.35 |
Post-Tx TG in mmol/L | 1.37 ± 0.81 | 1.24 ± 0.61 | 0.126 | ||
Pre-Tx HDL in mmol/L | 1.32 ± 0.40 | 0.794 | 1.26 ± 0.40 | 0.879 | 0.246 |
Post-Tx HDL in mmol/L | 1.32 ± 0.36 | 1.27 ± 0.41 | 0.285 | ||
Pre-Tx LDL in mmol/L | 3.12 ± 0.90 | 0.785 | 3.06 ± 1.01 | 0.078 | 0.543 |
Post-Tx LDL in mmol/L | 3.14 ± 0.92 | 3.15 ± 1.00 | 0.906 | ||
Pre-Tx NAFLD | 75 (35.05) | 0.125 | 32 (26.23) | 1 | 0.122 |
Post-Tx NAFLD | 70 (32.71) | 31 (25.41) | 0.16 |
- Citation: Lai RM, Lin S, Wang MM, Li N, Zhou JH, Lin XY, Chen TB, Zhu YY, Zheng Q. Tenofovir alafenamide significantly increased serum lipid levels compared with entecavir therapy in chronic hepatitis B virus patients. World J Hepatol 2023; 15(8): 964-972
- URL: https://www.wjgnet.com/1948-5182/full/v15/i8/964.htm
- DOI: https://dx.doi.org/10.4254/wjh.v15.i8.964